Prosecution Insights
Last updated: April 19, 2026

Xenon Pharmaceuticals Inc.

8 pending office actions

Portfolio Summary

8
Total Pending OAs
1
Final Rejections
7
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19094303 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Non-Final OA Mar 28, 2025
18746981 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS CARCANAGUE, DANIEL R 1621 Non-Final OA Jun 18, 2024
18679045 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Non-Final OA May 30, 2024
18648049 METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER SOROUSH, LAYLA 1622 Non-Final OA Apr 26, 2024
18415139 METHODS FOR TREATING PAIN SZNAIDMAN, MARCOS L 1628 Non-Final OA Jan 17, 2024
18540582 SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR ROZOF, TIMOTHY R 1625 Final Rejection Dec 14, 2023
18330100 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS LEE, CHIHYI NMN 1628 Non-Final OA Jun 06, 2023
18248663 USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER (S)-4-((1-BENZYLPYRROLIDIN-3-YL)(METHYL)AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL)BENZENESULFONAMIDE, TOGETHER WITH STRONG INDUCERS OF CYTOCHROME P450 3A4, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAVI.6 ACTIVITY FETTEROLF, BRANDON J 1626 Non-Final OA Apr 11, 2023

Managing Xenon Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month